Chugai Pharmaceutical : Announces the Decision of the Termination of Exclusive License Agreement on OBP-301 (Telomelysin), Oncolytic Viral Immunotherapy
October 19, 2021 at 01:32 pm IST
Share
October 19, 2021
Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number:
4519 (1st Section of Tokyo Stock Exchange)
Head office:
1-1,Nihonbashi-Muromachi2-Chome,Chuo-ku, Tokyo
President & CEO:
Osamu Okuda
Inquiries to:
Toshiya Sasai
Head of Corporate Communications Dept.
Tel: +81-(0)3-3273-0554
Chugai Announces the Decision of the Termination of Exclusive License Agreement on OBP-301 (Telomelysin), Oncolytic Viral Immunotherapy
Chugai Pharmaceutical Co., Ltd.announced that the company and Oncolys BioPharma Inc. (hereafter, "Oncolys") agreed to terminate the license agreement concluded between the two companies on April 8, 2019 (hereafter, "Agreement") for an oncolytic viral immunotherapy OBP-301 (Telomelysin: suratadenoturev) as follows. The effective date of the termination will be decided upon consultation with Oncolys, at the latest by October 2022. Upon termination of the Agreement, all rights Chugai may have with respect to OBP-301 will be returned to Oncolys. There will be no payment or receipt of milestone fees between the two companies.
Reasons for the Termination
Chugai entered into the Agreement with Oncolys on April 8, 2019, and has been developing OBP-301 in Japan. However, Chugai concluded that pursuing the development of the product through collaboration between the two companies will not maximize the product value of the drug. This decision is not attributable to any efficacy or safety issues regarding OBP-301. For the time being, Chugai will continue to conduct ongoing domestic clinical trials and transfer the initiative to Oncolys upon agreement between the two companies.
Details of the Agreement to be Terminated
The Agreement, which will be terminated, granted Chugai an exclusive license, with sublicensing rights, for development, manufacturing and marketing of OBP-301 in Japan and Taiwan as well as exclusive option rights concerning the worldwide development, manufacturing and marketing of OBP-301, excluding Japan, Taiwan, China, Hong Kong, and Macau.
Outline of the Counterparty to the Termination of the Agreement
Name: Oncolys BioPharma Inc.
Address: 4-1-28, Toranomon, Minato-ku, Tokyo, Japan
Title and Name of Representative: Yasuo Urata, President & CEO
Prospects
There is no impact on our consolidated results for the fiscal year ended December 2021.
###
Attachments
Original document
Permalink
Disclaimer
Chugai Pharmaceutical Co. Ltd. published this content on 19 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 October 2021 08:01:08 UTC.
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%).
Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).
Chugai Pharmaceutical : Announces the Decision of the Termination of Exclusive License Agreement on OBP-301 (Telomelysin), Oncolytic Viral Immunotherapy